Phosphorylated tau protein at threonine 181 effectively identified patients with Alzheimer’s disease, while the amyloid-beta 42 to phosphorylated tau 181 ratio showed potential for tracking disease progression. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.